Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
All patients who did not achieve an intracranial response demonstrated stable disease or non-progression by RANO criteria irrespective of cohort Median intracranial PFS of 19.3 months observed across combined cohorts of ivonescimab administered as monotherapy or in combination with chemotherapy No cases of intracranial bleeding were observed in these patients with brain metastases Detailed safety and anti-tumor activity updates from Phase II trial for ivonescimab plus chemotherapy in multiple NSCLC settings, including 1L squamous NSCLC MIAMI, March 22, 2024 BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today at the 2024 European Lung Cancer Congress (ELCC 2024) in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central Europea
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024Business Wire
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsBusiness Wire
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumBusiness Wire
- Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor [Yahoo! Finance]Yahoo! Finance
SMMT
Sec Filings
- 4/25/24 - Form DEF
- 4/15/24 - Form 4
- 4/15/24 - Form 3
- SMMT's page on the SEC website